Neurolign Technologies, Inc. Acquires Neuro Kinetics

Sep 30, 2019

On September 20th, 2019, Neurolign Technologies Inc. (“Neurolign”) announced the acquisition of Neuro Kinetics Inc. “The acquisition of Neuro-Kinetics accelerates Neurolign’s mission to research, develop and provide access to world-class diagnostics and targeted pharmaceutical therapeutics, improving the lives of patients suffering from neurological disorders, initially beginning with concussion,” said Eugene Melnyk, Neurolign Chairman and Chief Executive Officer.

Neurolign Technologies is dedicated to creating a quantum shift in the diagnosis and treatment of neurodegenerative disease. Through the unique combination of high precision medical devices as well as specialty formulations and drug delivery technologies, Neurolign is creating a revolutionary approach to the assessment and treatment of brain injury and disease. Whether you are a patient or a medical professional, our world-class diagnostics and novel therapeutics can support the pursuit of optimal brain health and wellness. Neurolign was established by Eugene Melnyk, the founder of multiple healthcare companies, including Biovail Corporation (acquired by Bausch Health, NYSE: BHC), and is the current owner of the Ottawa Senators Hockey Club. Read the press release here. Additional information regarding Neurolign is available at neurolign.com.